A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Regentis Biomaterials Ltd., a regenerative medicine company, develops and commercializes tissue repair solutions in the United States. It offers Gelrin, a platform based on hydrogel matrix of polyethylene glycol diacrylate and denatured fibrinogen for the treatment and regeneration of damaged or diseased tissue; and GelrinC, a cell-free and off-the-shelf hydrogel, which is in Phase II clinical trial for the treatment of cartilage injuries in the knee. The company was incorporated in 2004 and is based in Herzliya, Israel.
Financial Summary
| Share Statistics | RGNT | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $9.0 | $252.6 | 6% |
|
| Shares Out (Mil) | 1.0 | 52.3 | 4% |
|
| Institutional Ownership | 83.9% | 92.1% | 52% |
|
| Float (Mil) | 2.8 | 40.2 | 7% |
|
| Beta | na | 0.95 | na |
|
| Avg Daily Volume (000s) | 144 | 455 | 40% |
|
| Price Change (52-week) |
na | 52.9% | na |
|
| Growth | RGNT | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 13.6% | na |
|
| Net Income (5yr) | (102.4%) | (9.9%) | 2% |
|
| EPS (5yr) | (53.5%) | 16.0% | 3 |
|
| Dividends (5yr) | na | 0.0% | na |
|
| Cash Flow (5yr) | 126.3% | (15.6%) | 99% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | na | na | na | |
| Current EPS | na | na | na | |
| Month Ago EPS | na | na | na | |
| # Rev Up | na | na | na | |
| # Rev Down | na | na | na | |
| Three Months Ago EPS | na | na | na | |
| Year/Year Chg | na | na | na | |
| Financials | RGNT | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | na | $38 | na |
|
| Net Income (TTM) (Mil) | ($14) | ($43) | 27% |
|
| EPS (TTM) | ($24.159) | ($1.600) | 2% |
|
| Operating Cash Flow (TTM) (Mil) | ($1) | ($31) | 29% |
|
| Net Cash Flow (TTM) (Mil) | na | $5 | na |
|
| Long-Term Debt (Q1) (Mil) | $0 | $5 | 0% |
|
| Enterprise Value (Q1) (Mil) | $16 | $180 | 10% |
|
| Valuation | RGNT | Industry Median |
Percentile (All Stocks) |
|
| P/B | 1.89 | 2.56 | 49% |
|
| P/E | na | 19.0 | na |
|
| Dividend Yield | na | 0.0% | na |
|
| PEG (5yr hist) | na | 0.9 | na |
|
| Ratios | RGNT | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | na | 63.8% | na |
|
| Net Margin | na | (67.3%) | na |
|
| ROA | (337.0%) | (49.8%) | 1% |
|
| ROE | 75.1% | (55.5%) | 95% |
|
| Liabilities to Assets | 37.7% | 30.3% | 28% |
|
| F-Score | 2 | 3 | na |
|
Regentis Biomaterials Ltd. did not pass any screens on 7/31/2026.
